bluuebunny/crossref_metadata_2025_split huggingface dataset:
Progress in the correlation between PTPN12 gene expression and human tumors
Authors: Huo Yu-hu , Wang Ya-ni , Meng Ling-bing , Zhang Ai-li , Liu Bin 
Published: June 2020

Abstract

Background:
The global morbidity of cancer is rising rapidly. Despite advances in molecular biology, immunology, and cytotoxic and immune-anticancer therapies, cancer remains a major cause of death worldwide. Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a new member of the cytoplasmic protein tyrosine phosphatase family, isolated from a cDNA library of adult colon tissue. Thus far, no studies have reviewed the correlation between PTPN12 gene expression and human tumors.

Methods:
This article summarizes the latest domestic and international research developments on how the expression of PTPN12 relates to human tumors. The extensive search in Web of Science and PubMed with the keywords including PTPN12, tumor, renal cell carcinoma, proto-oncogenes, tumor suppressor genes was undertaken.

Results:
More and more studies have shown that a tumor is essentially a genetic disease, arising from a broken antagonistic function between proto-oncogenes and tumor suppressor genes. When their antagonistic effect is out of balance, it may cause uncontrolled growth of cells and lead to the occurrence of tumors. PTPN12 is a tumor suppressor gene, so inhibiting its activity will lead directly or indirectly to the occurrence of tumors.

Conclusion:
The etiology, prevention, and treatment of tumors have become the focus of research around the world. PTPN12 is a tumor suppressor gene. In the future, PTPN12 might serve as a novel molecular marker to benefit patients, and even the development of tumor suppressor gene activation agents can form a practical research direction.
Acute pneumonitis and diffuse alveolar hemorrhage secondary to silicone embolism
Authors: Bejarano Alejandro , Bautista Diego F. , Sua Luz F. , Pérez Bladimir , Lores Juliana , Aguirre Marisol , Fernández-Trujillo Liliana 
Published: June 2020

Abstract

Rationale:
Polydimethylsiloxane, commonly referred as silicone, is an inert liquid compound used in esthetic procedures due to its durability and thermal stability, yet the application of non-pure silicone generates risks. One of the complications is systemic embolism syndrome which is presents with fever, hypoxemia, and progression to respiratory failure, diffuse alveolar damage and alveolar hemorrhage, as well as neurological alterations in one-third of the cases. Management is strictly supportive. We present the case of acute pneumonitis with alveolar hemorrhage after silicone injection.

Patient concerns:
25-year-old transsexual man, who consulted 48 hours after liquid silicone injection in the buttocks and trochanteric area, with progressive dyspnea and chest tightness, with rapid progression to respiratory failure.

Diagnosis:
Clinical diagnosis of silicone embolism was made. Chest x-ray and CT angiography showed diffuse alveolar infiltrates and pleural effusion without evidence of acute venous thromboembolism. Bronchoscopy plus bronchoalveolar lavage showed hemorrhagic fluid, 60% macrophages with hemosiderin in cytology and negative cultures.

Intervention:
Sedation, relaxation, pronation, and protective ventilation were implemented until hemodynamic stabilization; as well as IV steroids and antibiotics.

Outcomes:
Clinical progress was slow towards improvement with resolution of radiological or physical abnormalities. Despite severity, the patient improved satisfactorily without late sequelae.

Lessons:
Silicone injection can trigger phenomena similar to that seen in fat embolism causing inflammation and immune response activation that lead to alveolar hemorrhage, diffuse alveolar damage, and acute respiratory distress syndrome. We reported pulmonary complications related to the illegal use of injected silicone for esthetic procedures.
Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
Authors: Ren Cuicui , Wang Lili , Sun Weihui , Ma Lei , Dong Zhi , Hao Anhua , Zhou Lin , Li Fengzhu , Ma Wenjie 
Published: June 2020

AbstractTo observe the efficacy of telbivudine in chronic hepatitis B (CHB) women with high viral load during pregnancy and the long-term effects on intelligence, growth, and development of the newborns.A total of 87 patients were included. Forty-two patients received telbivudine orally 600 mg per day and treatment initiated from 12 weeks after gestation until the 12th postpartum week. Forty-five patients were untreated according to principle of informed consent. All infants received injection of hepatitis B immune globulin (HBIG; 200 IU) and were vaccinated with recombinant HBV vaccine. Wechsler preschool intelligence scale was used to assess mental and neuropsychological developments of these children till they were 6 years old. Data including serum HBV DNA viral load, Apgar score, and scores of Wechsler preschool intelligence scale were analyzed and compared.Levels of both serum HBV DNA and ALT in patients who received telbivudine were significantly decreased at the 12th week after delivery, compared with baseline levels (P < .01). No significant changes were observed in patients not receiving telbivudine (P > .05). Serum HBV DNA and ALT levels at the 12th week after delivery in the telbivudine group were significantly lower than those of patients without telbivudine (P < .01). The serum HBsAg-positive rate in neonates 7 months of age was 0%, which was significantly lower than that in control group (11.11%) (P < .05). No statistical differences were observed between the 2 groups regarding maternal cesarean section rate, adverse pregnancy rate, postpartum bleeding rate, neonatal body mass, Apgar score, neonatal malformation incidence, or intelligence development of newborn.Telbivudine is effective to reduce the viral load in CHB mothers with high viral load and could lower the perinatal transmission rate. Both mental and physical development in neonates with exposure to telbivudine during perinatal period were similar to those without telbivudine exposure.
The “criminal” artery of de Winter may be the left circumflex artery
Authors: Shao Dongpu , Yang Na , Zhou Shanshan , Cai Qingyuan , Zhang Rangrang , Zhang Qian , Wei Zhaoyang , Li Hang , Zheng Yang , Tong Qian , Zhang Zhiguo 
Published: June 2020

Abstract

Rationale:
De Winter et al first described a new ST-segment elevation myocardial infarction (STEMI)-equivalent pattern associated with acute occlusion of the left anterior descending coronary artery (LAD). Studies show that this pattern has a positive predictive value of 95.2% to 100%. However, some cases of non-STEMI, caused by acute right coronary artery or LAD diagonal branch occlusion, have been reported, which exhibit electrocardiogram (ECG) changes similar to the de Winter pattern. Few cases of de Winter ECG pattern caused by left circumflex artery (LCX) stenosis have been reported.

Patient concerns:
A 57-year-old man was admitted to the emergency department 12 hours after suffering from oppressive chest pain and diaphoresis. The patient had a history of diabetes and smoking. An initial ECG showed atrial fibrillation, upsloping ST-segment depression at the J point, followed by peaked, positive T waves in leads V2 to V6 and slight ST-segment elevation in lead aVR, with poor R-wave progression. Coronary angiography showed tubular stenosis (up to 95%) of the proximal portion of the LCX.

Diagnosis:
LCX stenosis led to a diagnosis of non-STEMI.

Interventions:
Left coronary artery stenosis was successfully treated with angioplasty and insertion of a drug-eluting stent.

Outcomes:
The patient's chest pain resolved completely after stent implantation. No myocardial infarction occurred during the 6-month follow-up period.

Lessons:
De Winter ECG pattern cannot be presumed to be associated with LAD stenosis and 18-lead ECG is required to support the identification of the “criminal” artery and to rule out posterior myocardial infarction.
General internal medicine and family medicine journals
Authors: Sebo Paul 
Published: June 2020

Abstract
Like research in general internal medicine, family medicine research can play an important role in improving medical knowledge. We aimed to compare articles published in family medicine journals with articles published in general internal medicine journals. In this bibliometric study, we retrieved 658 randomly selected quantitative articles published in 2016 in 18 high impact factor journals of family medicine and general internal medicine. We extracted the following data: author (gender, number of publications, and place of residence of the first author), paper (number of participants, study design) and journal characteristics (journal discipline, 2015 impact factor). We compared the two groups of articles, using multivariate logistic regressions adjusted for impact factor and intra-cluster correlations. The first author of the articles published in family medicine journals, compared to general internal medicine journals, was more often a woman (OR 2.8 [95%CI 1.8–4.4], P-value < .001), living in the Western world (OR 14.4 [95%CI 6.0–34.4], P-value < .001), and a less experienced researcher (<5 vs >15 publications: OR 2.4 [95%CI 1.5–4.0], P-value .01). In addition, these studies generally included more participants (>1000 vs <100: OR 3.5 [95%CI 1.4–8.6], P-value .02). There was no statistically significant difference in the study design between the two groups of articles (P-value .25). Despite some differences between the two groups of articles, studies published in family medicine journals do not appear to be any less ambitious in terms of study design and sample size than those published in general internal medicine journals.
Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease
Authors: Shi Xiao-yan , Fan Si-min , Shi Guo-mei , Yao Jia , Gao Yang , Xia Yu-guo , Chen Qiu 
Published: June 2020

Abstract

Background:
Non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis, which is considered as the hepatic manifestation of metabolic syndrome, has a great prevalence all over the world. New drugs are urgently needed for the treatment of NAFLD. This review will be to assess the efficacy and safety of omega-3 polyunsaturated fatty acids (n-3 PUFAs) on liver-related outcomes (liver histology and liver enzymes) in patients with NAFLD.

Methods:
We will search 5 databases for relative studies: Medline, the Cochrane Library, EMBASE, Web of Science, and ClinicalTrials.gov and identified all reports of randomized controlled trials published prior to July 2020. Two authors will independently scan the articles searched, extract the data from articles included, and assess the risk of bias by Cochrane tool of risk of bias. Disagreements will be resolved by discussion among authors. All analysis will be performed based on the Cochrane Handbook for Systematic Reviews of Interventions. Fixed-effects model or random-effects model will be used to calculate pooled estimates of weighted mean difference with 95% confidence intervals.

Results:
This systematic review aims to examine the effect of n-3 PUFAs on liver histology and liver enzymes in patients with NAFLD.

Conclusions:
These findings will provide guidance to clinicians and patients on the use of n-3 PUFAs for NAFLD.

Ethics and dissemination:
This study is a protocol for a systematic review of n-3 PUFAs as a treatment of NAFLD patients. This review will be published in a journal and disseminated in print by peer-review.

Systematic review registration:
INPLASY202050008.
Effect of febuxostat on blood pressure in hyperuricemic patients
Authors: Yao Jia , Shi Xiaoyan , Fan Simin , Gao Yang , Hu Hengchang , Wang PanPan , Chen Qiu 
Published: June 2020

Abstract

Background:
Increasing evidence connects serum uric acid (sUA) with hypertension. Previous studies on the efficacy of febuxostat on blood pressure (BP) in hyperuricemic patients have provided conflicting results. Thus, we aim to perform a systematic review and meta-analysis to investigate the efficacy of febuxostat on BP.

Methods:
Five electronic databases (included The Cochrane Library, MEDLINE, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) will be searched. Randomized controlled trials will be included if they recruited hyperuricemic participants for assessing the effect of febuxostat on BP versus control (placebo, no treatment, and other therapeutic agents). The primary outcome will be BP, secondary outcomes will be sUA, serum creatinine, and estimated glomerular filtration rate. Relevant literature search, data extraction, and quality assessment will be performed by 2 researchers independently, and the third researcher will be involved in a discussion for any disagreements. All analyses will be performed based on the Cochrane Handbook for Systematic Reviews of Interventions. Stata 12.0 software will be used for statistical analysis. The effect size of dichotomous data will be measured using the odds ratio , and the effect size of continuous data will be measured using the standardized mean difference. And 95% confidence intervals will be calculated. Heterogeneity will be tested by χ
2-based Cochran Q statistic and I
2 statistic. Sensitivity analysis and subgroup analysis will be used to observe changes in the pooled effect size and heterogeneity between included studies, to assess the reliability and stability of the pooled results. The funnel plot and Egger's and Begg's tests will be used to judge publication bias, and the trim and fill method will be used to correct the funnel asymmetry caused by publication bias. P < .05 will be considered to indicate a statistically significant result.

Results:
This systematic review and meta-analysis will be to assess the efficacy of febuxostat on BP.

Conclusions:
Our findings will show the effect of febuxostat on BP in hyperuricemic patients. And such a study may find a new therapeutic option for hypertensive patients and assist clinicians and health professionals make clinical decisions.

Ethics and dissemination:
This study is a protocol for systematic review and meta-analysis of the effect of febuxostat on BP in hypertensive patients. This systematic review and meta-analysis will be published in a journal and disseminated in print by peer-review.

INPLASY registration number:
INPLASY202050031.
Effects of bushen qianggu method for primary osteoporosis
Authors: Chen Guocai , Guan Yingxin , Ye Xiangling , Chen Guoqian , Du Jianping , Liu Wengang , Zhao Chuanxi , Yao Nan , Xu Xuemeng 
Published: June 2020

Abstract

Background:
Primary osteoporosis (POP) is one of the most common orthopedic diseases with a high risk of fracture. Effective treatment of POP is of great significance to reduce the rate of disability and improve the quality of life. Bushen qianggu (BSQG) is a classical method of TCM in treating POP. However, there is no systematic review related to BSQG for POP. The purpose of this study is to provide a comprehensive and reliable evaluation of the clinical evidence of BSQG in the treatment of POP.

Methods and analysis:
Relevant randomized controlled trial literature evaluating the effect of BSQG on patients with POP will be obtained by searching the PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China national knowledge infrastructure database, Wan fang database, Chongqing VIP information, and SinoMed from their inception to May 2020. Two researchers will select and evaluate qualified studies independently. The bone mineral density value and the incidence of fractures will be accepted as the primary outcomes. The meta-analyses will be performed by using the RevMan 5.3.

Results:
This study will provide a comprehensive evaluation of the efficacy and safety of BSQG method for patients with POP.

Conclusion:
The conclusion of our systematic review will provide evidence to judge whether BSQG is an effective intervention for patients with POP.
Trial registration number: 10.17605/OSF.IO/ZMX3W.
A-kinase interacting protein 1 high expression correlates with advanced tumor stage and poor overall survival in surgical patients with clear cell renal cell carcinoma
Authors: Peng Huimin , Zhang Rong , Zhang Hao 
Published: June 2020

Abstract
The present study aimed to detect the A-kinase interacting protein 1 (AKIP1) expression in clear cell renal cell carcinoma (ccRCC) tumor tissues and adjacent tissues, and further investigate the correlation of tumor AKIP1 expression with clinicopathological features and survival profile in ccRCC patients.
Totally 210 ccRCC patients who underwent resection were retrospectively reviewed, and their tumor and adjacent tissue specimens were acquired for immunohistochemical detection of AKIP1 expression. The survival data of patients were collected for overall survival (OS) assessment.
AKIP1 was upregulated in ccRCC tumor tissues compared with adjacent tissues (P < .001). Tumor AKIP1 expression was positively associated with T stage (P = .019), N stage (P = .032), and TNM stage (P = .005) in ccRCC patients. According to AKIP1 expression in tumor tissues, all patients were grouped as AKIP1 low and high expression (AKIP1 high expression were further divided into AKIP1 high+, high++, and high+++ expression). OS was the lowest in the patients with AKIP1 high+++ expression, followed by those with AKIP1 high++ expression and AKIP1 high+ expression, and then patients with AKIP1 low expression (P < .001). Furthermore, multivariate Cox regression exhibited tumor AKIP1 high expression (P = .017), age (>60 years) (P = .030), pathological grade (G2/G3 vs G1) (P = .037), and TNM stage (II/III vs I) (P < .001) were independent predictive factors for decreased OS in ccRCC patients.
AKIP1 presents potency to be a novel biomarker for tumor progression and prognosis surveillance in ccRCC.
Safety Audits in the Emergency Department
Authors: Tenedero Christine Bernice , Soliman Aiah , Samaan M. Constantine , Kam April Jacqueline 
Published: June 2020

Objectives
This study aims to better understand factors that impact management of patients with diabetic ketoacidosis (DKA) in the pediatric emergency department (ED) by novel application of the threat-and-error model, commonly used in the aviation industry.

Methods
This study was a retrospective chart review of all patients diagnosed with DKA and managed in our pediatric ED during a 1-year period. A “flight plan” was created for each patient's ED visit, from triage to final disposition. Each flight was analyzed with the goal of identifying threats and errors that may impact patients' clinical status or management. Particular focus was placed on physicians' adherence to hospital and provincial DKA protocols. Unintended patient states or outcomes were also noted.

Results
A total of 46 patient flights were outlined and analyzed. A total of 146 threats were identified, affecting 43 (93%) patient flights. No flight was error-free. Errors in communication and lack of adherence to protocol were the most common types of errors. Unintended patient states occurred in 30 cases (65%), some of which were preceded by at least 1 error. There were no cases of cerebral edema or death.

Conclusions
It is important to identify and appropriately mitigate threats and errors that commonly occur during initial management of DKA in the ED to prevent unintended states and patient morbidity. This study demonstrates the threat-and-error model as a potentially useful tool for focusing quality improvement initiatives in the pediatric ED setting.
Radiotherapy for Non-Hodgkin Lymphomas
Authors: Imber Brandon S. , Yahalom Joachim 
Published: June 2020

AbstractRadiotherapy (RT) plays a diverse and essential role in the contemporary management of non-Hodgkin lymphoma (NHL) and remains the single most powerful monotherapeutic intervention for both aggressive and indolent subtypes. Over the past decade, there have been significant advancements in radiation oncology practice, which have made modern treatments safer and more conformal. Despite this sophistication and evidence supporting a continued role for RT, numerous data suggest that utilization is on the decline. In this review, we discuss the rationale for RT in 4 commonly encountered scenarios: combined modality therapy for limited-stage aggressive NHL, consolidation therapy for advanced-stage aggressive NHL, and the changing roles of salvage RT for relapsed/refractory NHL in an era of new frontiers such as cellular therapies. We also evaluate current strategies to treat indolent histologies. We conclude with perspectives on how RT for the hematological malignancies may continue to evolve.
Caulobacter soli sp. nov., isolated from soil sampled at Jiri Mountain, Republic of Korea
Authors: Yang Yuanyuan , Jin Chun-Zhi , Jin Feng-Jie , Li Taihua , Lee Jong-Min , Kim Chang-Jin , Lee Hyung-Gwan , Jin Long 
Published: June 2020

A Gram-stain-negative, yellow-pigmented, aerobic, non-spore-forming, motile with a single polar flagellum and rod-shaped bacterium, Ji-3-8T, was isolated from a soil sample taken from Jiri Mountain, Republic of Korea. Comparative 16S rRNA gene sequence studies showed the isolate had clear affiliation with

Alphaproteobacteria

and the closest relatedness to

Caulobacter rhizosphaerae

KCTC 52515T,

Caulobacter henricii

ATCC 15253T,

Caulobacter segnis

ATCC 21756T,

Caulobacter hibisci

THG-AG3.4T,

Caulobacter flavus

RHGG3T and

Caulobacter vibrioides

CB51T showing 99.1, 98.9, 97.7, 97.6, 97.5 and 97.4 % 16S rRNA gene sequence similarity, respectively, and 94.7–96.5 % to the remaining species of genus

Caulobacter

. The predominant ubiquinone was Q-10 and the major fatty acids were C18 : 1
ω7c 11-methyl, C16 : 0, summed feature 8 (C18 : 1
ω6c and/or C18 : 1
ω7c) and summed feature 3 (C16 : 1
ω6c and/or C16 : 1
ω7c). The major polar lipids were found to be phosphatidylglycerol, two unidentified phosphoglycolipid and two unidentified glycolipids. The G+C content of the genomic DNA of strain Ji-3-8T was 68.1 mol%. Average nucleotide identity and digital DNA–DNA hybridization values of strain Ji-3-8T with

C. rhizosphaerae

KCTC 52515T,

C. henricii

ATCC 15253T,

C. segnis

ATCC 21756T,

C. flavus

RHGG3T and

C. vibrioides

were 79.7–87.7% and 23.0–34.3%, respectively. Based on the polyphasic evidence, it is proposed that strain Ji-3-8T forms a novel species in the genus

Caulobacter

, for which the name Caulobacter soli sp. nov. is proposed. The type strain is Ji-3-8T (=CCTCC AB 2019389T=KCTC 72990T).